Latest News-CSTONE PHARMACEUTICALS Mediaroom_Page

CStone announces positive GAVRETO® (pralsetinib) registrational study data for first-line treatment of advanced RET fusion-positive non-small cell lung cancer and plans to submit a new indication application

* Key efficacy data showed that GAVRETO demonstrated deep and durable clinical activity in Chines...

2021-06-24 08:05 5715

CStone announces first prescriptions of precision therapy GAVRETO® (pralsetinib) issued across China for the treatment of adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer after platinum-based chemotherapy

SUZHOU, China, June 21, 2021 /PRNewswire/ -- GAVRETO® (pralsetinib), a precision therapy discovered...

2021-06-21 13:06 2569

CStone Announces the First-in-Class Registrational Clinical Trial of Sugemalimab Met its Primary Endpoint in Stage III NSCLC and Plans to Submit a New Drug Application

* Sugemalimab becomes the world's first anti-PD-1/PD-L1 monoclonal antibody to successfully impro...

2021-05-28 08:10 7317

CStone Announces Acceptance of New Drug Application in Hong Kong for Avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumor

SUZHOU, China, May 12, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leadin...

2021-05-12 14:09 2523

CStone Announces NMPA Acceptance of New Drug Application of Selective Inhibitor GAVRETO(R) (Pralsetinib) with Priority Review Designation for the Treatment of Advanced or Metastatic RET-Altered Thyroid Cancer Patients

SUZHOU, China, April 26, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leadin...

2021-04-26 21:14 3272

CStone Announces China NMPA New Drug Approval of Precision Therapy AYVAKIT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor

SUZHOU, China, March 31, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leadin...

2021-03-31 18:20 6253

CStone Pharmaceuticals Reports Financial Results and Business Highlights for Full-year 2020

SUZHOU, China, March 25, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leadin...

2021-03-25 22:03 3841

CStone Announces New Drug Approval of GAVRETO(R) (pralsetinib) as First Selective RET Inhibitor in China, Providing a New Therapy for a Subset of Non-Small Cell Lung Cancer Patients

* GAVRETO has been approved for the treatment of adults with locally advanced or metastatic RET f...

2021-03-24 10:46 4758

CStone Pharmaceuticals Reports Efficacy and Safety Data from the ARROW Trial of Pralsetinib in Chinese Patients with Advanced RET Fusion-positive Non-Small Cell Lung Cancer after Platinum-based Chemotherapy at IASLC WCLC 2020

SUZHOU, China, Jan. 28, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEx: 2616), a leadi...

2021-01-28 10:15 4123

CStone's Partner Blueprint Medicines Announces U.S. FDA Approval of GAVRETO (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer

SUZHOU, China, Dec. 10, 2020 /PRNewswire/ -- The partner of CStone Pharmaceuticals ("CStone", HKEX:...

2020-12-10 08:30 3446

ESMO ASIA Congress 2020 | CStone Pharmaceuticals announces the results of GEMSTONE-302, Sugemalimab has the potential to provide a new treatment option for patients with advanced NSCLC

SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leadi...

2020-11-23 09:30 3384

CStone Pharmaceuticals Announces China's NMPA has Accepted its New Drug Application for anti-PD-L1 Monoclonal Antibody Sugemalimab in First-Line Advanced NSCLC

* Currently, there is no anti-PD-L1 monoclonal antibody approved for stage IV NSCLC inChina * A...

2020-11-12 10:58 3983

CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate

* CStone to acquire exclusive rights for development and commercialization outsideSouth Korea for...

2020-10-29 07:15 3198

CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)

* CStone to out-license to EQRx exclusive rights to two late-stage immuno-oncology assets for dev...

2020-10-27 07:23 2986

CStone Announces Completion of $200 million Share Sale to Pfizer

SUZHOU, China, Oct. 12, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) announce...

2020-10-12 08:05 5696

CStone Pharmaceuticals Announces Updated Results from Two Studies of Its Anti-PD-L1 Monoclonal Antibody Sugemalimab (CS1001) At 2020 CSCO Annual Meeting

* CS1001-201 study demonstrated an objective response rate (ORR) of 44.7%, a complete response (C...

2020-09-25 15:28 3674

CStone Announces Preliminary Results from a Bridging Study of Avapritinib in Chinese Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors at the 2020 CSCO Annual Meeting

* Avapritinib has demonstrated strong anti-tumor activity in Chinese patients with PDGFRA D842V m...

2020-09-25 14:53 3686

CStone Receives US FDA IND Clearance for CS1001-201 Study to Evaluate Anti-PD-L1 Monoclonal Antibody Sugemalimab Monotherapy in R/R ENKTL

SUZHOU, China, Aug. 31, 2020 /PRNewswire/ -- CStone Pharmaceuticals (SUZHOU) Co., Ltd. ("CStone", H...

2020-08-31 11:35 3414

CStone Pharmaceuticals Reports Financial Results for the First Half of 2020

SUZHOU, China, Aug. 19, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616), a leadi...

2020-08-19 09:33 4141

CStone submits new drug application for the targeted therapy avapritinib in Taiwan for the treatment of adults with advanced PDGFRA exon 18 mutant gastrointestinal stromal tumor

SUZHOU, China, March 27, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HK...

2020-03-27 14:02 1451